NovaBridge Biosciences (NBP) Revenue History
Annual and quarterly revenue from 2017 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
NBP Revenue Growth
Revenue Breakdown (FY 2023)
NBP's revenue distribution by segment and geography for fiscal year 2023
By Product/Segment
NBP Revenue Analysis (2017–2024)
As of May 8, 2026, NovaBridge Biosciences (NBP) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, NBP's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $1.54 billion in 2020.
Revenue diversification analysis shows NBP's business is primarily driven by Licensing and Collaboration (61%), and Supply Of Investigational Products (39%). With over half of revenue concentrated in Licensing and Collaboration, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including RCUS (+67.4% YoY), KYMR (-12.6% YoY), and ARQT (+95.3% YoY). Compare NBP vs RCUS →
NBP Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| NBPCurrent | $0 | - | - | - | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 ARQT | $376M | +95.3% | - | -3.3% |
NBP Historical Revenue Data (2017–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | -100.0% | $0 | - | $-375,358,000 | - |
| 2023 | $4.5M | +141.9% | $4.5M | 100.0% | $-511,162,000 | -11395.1% |
| 2022 | $-10,697,247 | -112.2% | $-248,800,000 | 2325.8% | $-366,078,000 | 3422.2% |
| 2021 | $88.0M | -94.3% | $41.6M | 47.3% | $-2,071,307,000 | -2353.1% |
| 2020 | $1.54B | +5042.2% | $1.54B | 100.0% | $155.6M | 10.1% |
| 2019 | $30.0M | -44.2% | $30.0M | 100.0% | $-1,464,968,000 | -4883.2% |
| 2018 | $53.8M | +365.4% | $53.8M | 100.0% | $-438,638,000 | -815.6% |
| 2017 | $11.6M | - | $11.6M | 100.0% | $-280,955,000 | -2431.2% |
See NBP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NBP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NBP vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNBP — Frequently Asked Questions
Quick answers to the most common questions about buying NBP stock.
Is NBP's revenue growth accelerating or slowing?
NBP TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is NBP's long-term revenue growth rate?
NovaBridge Biosciences's 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is NBP's revenue distributed by segment?
NBP reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2024 are available for download. Segment mix reveals concentration and diversification trends.